Suppressing BCL-XL increased the high dose androgens therapeutic effect to better induce the Enzalutamide-resistant prostate cancer autophagic cell death

Most patients with advanced prostate cancer (PCa) initially respond well to androgen deprivation therapy (ADT) with antiandrogens, but most of them eventually become resistant to ADT. Here, we found that the antiandrogen Enzalutamide-resistant (EnzR) PCa cells can be suppressed by hyper-physiologica...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Zhendong, Sun, Yin, You, Bosen, Zhang, Meng, Huang, Chiping, Yu, Junfeng, You, Xiangyun, Wu, Denglong, Chang, Chawnshang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801470/
https://www.ncbi.nlm.nih.gov/pubmed/33431795
http://dx.doi.org/10.1038/s41419-020-03321-z

Ejemplares similares

Ejemplares similares